




Searching News Database: sorafenib
HSMN NewsFeed - 12 Mar 2020
F1 Oncology Changes Name To EXUMA Biotech; Announces New Round Of Financing To Advance Cellular Therapies
F1 Oncology Changes Name To EXUMA Biotech; Announces New Round Of Financing To Advance Cellular Therapies
HSMN NewsFeed - 27 Aug 2015
Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer
Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer
HSMN NewsFeed - 7 Jul 2014
Nexavar(R) (sorafenib tablets) now Approved in Canada for the Treatment of Differentiated Thyroid Cancer
Nexavar(R) (sorafenib tablets) now Approved in Canada for the Treatment of Differentiated Thyroid Cancer
HSMN NewsFeed - 11 Jun 2014
Lilly Announces Top-Line Results Of Phase III Hepatocellular Carcinoma Trial
Lilly Announces Top-Line Results Of Phase III Hepatocellular Carcinoma Trial
HSMN NewsFeed - 15 May 2013
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Advanced Liver Cancer
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Advanced Liver Cancer
HSMN NewsFeed - 19 Feb 2013
Curis Appoints Ali Fattaey, Ph.D. as President and Chief Operating Officer
Curis Appoints Ali Fattaey, Ph.D. as President and Chief Operating Officer
HSMN NewsFeed - 24 Apr 2012
Nordion Announces Europe-Focused Phase III Clinical Trial for TheraSphere(R) Liver Cancer Treatment
Nordion Announces Europe-Focused Phase III Clinical Trial for TheraSphere(R) Liver Cancer Treatment
HSMN NewsFeed - 12 Oct 2011
Onyx Pharmaceuticals and Bayer Healthcare Restructure Global Oncology Partnership
Onyx Pharmaceuticals and Bayer Healthcare Restructure Global Oncology Partnership
HSMN NewsFeed - 15 Sep 2011
Curis, Inc. Announces Appointment of Robert Martell, M.D., Ph.D. to its Board of Directors
Curis, Inc. Announces Appointment of Robert Martell, M.D., Ph.D. to its Board of Directors
HSMN NewsFeed - 19 Jan 2011
Jennerex Names Ursula Fritsch, PharmD, as Vice President, Regulatory Affairs
Jennerex Names Ursula Fritsch, PharmD, as Vice President, Regulatory Affairs
HSMN NewsFeed - 19 Nov 2010
VeriStrat(R) Test Identifies Lung Cancer Patients Benefiting from Combination Therapy
VeriStrat(R) Test Identifies Lung Cancer Patients Benefiting from Combination Therapy
HSMN NewsFeed - 21 Oct 2010
Jennerex Names Dr. Mark P. Backer as Senior Vice President of Technical Operations
Jennerex Names Dr. Mark P. Backer as Senior Vice President of Technical Operations
HSMN NewsFeed - 9 Feb 2010
Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
HSMN NewsFeed - 23 Oct 2009
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Patients With Non-Responsive Thyroid Cancer
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Patients With Non-Responsive Thyroid Cancer
HSMN NewsFeed - 1 Jun 2009
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer
HSMN NewsFeed - 15 Aug 2008
Onyx Pharmaceuticals Names Juergen Lasowski, Ph.D. as Senior Vice President of Corporate Development
Onyx Pharmaceuticals Names Juergen Lasowski, Ph.D. as Senior Vice President of Corporate Development
HSMN NewsFeed - 16 May 2008
Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
HSMN NewsFeed - 13 Mar 2008
Sequence of Treatments May Induce Clinical Response in Metastatic Renal Cell Carcinoma Patients
Sequence of Treatments May Induce Clinical Response in Metastatic Renal Cell Carcinoma Patients
HSMN NewsFeed - 18 Feb 2008
Bayer and Onyx Provide Update on Phase 3 Trial of Nexavar in Patients With Non-Small Cell Lung Cancer
Bayer and Onyx Provide Update on Phase 3 Trial of Nexavar in Patients With Non-Small Cell Lung Cancer
HSMN NewsFeed - 12 Feb 2008
Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
HSMN NewsFeed - 30 Oct 2007
Nexavar Becomes First and Only Approved Treatment of Hepatocellular Carcinoma in Europe
Nexavar Becomes First and Only Approved Treatment of Hepatocellular Carcinoma in Europe
HSMN NewsFeed - 27 Aug 2007
Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
HSMN NewsFeed - 27 Jun 2007
Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer
Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer
HSMN NewsFeed - 4 Jun 2007
Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
HSMN NewsFeed - 12 Feb 2007
Nexavar Shown to Significantly Extend Survival for Patients with Advanced Liver Cancer
Nexavar Shown to Significantly Extend Survival for Patients with Advanced Liver Cancer
HSMN NewsFeed - 10 Jan 2007
Bayer and Onyx Announce Pivotal Nexavar(R) Kidney Cancer Study Published in New England Journal of Medicine
Bayer and Onyx Announce Pivotal Nexavar(R) Kidney Cancer Study Published in New England Journal of Medicine
HSMN NewsFeed - 4 Dec 2006
Phase III Trial of Nexavar in Patients with Advanced Melanoma Does Not Meet Primary Endpoint
Phase III Trial of Nexavar in Patients with Advanced Melanoma Does Not Meet Primary Endpoint
HSMN NewsFeed - 23 Jul 2006
Nexavar(R) Approved by European Commission for the Treatment of Advanced Kidney Cancer
Nexavar(R) Approved by European Commission for the Treatment of Advanced Kidney Cancer
Additional items found! 24

Members Archive contains
24 additional stories matching:
sorafenib
(Password required)
sorafenib
(Password required)